ESC Premium Access

Remnant lipoprotein is a residual risk of future cardiovascular events in patients with stable coronary artery disease and on statin LDL-cholesterol levels less than 70 mg/dl

Congress Session

About the speaker

Doctor Yuki Fujihara

Kofu Jonan Hospital, Kofu (Japan)
0 follower

6 more presentations in this session

Intensification of lipid lowering therapy before and after publication of the IMPROVE-IT trial: A temporal analysis from the SPUM-ACS cohort

Speaker: Doctor B. Gencer (Geneva, CH)

Thumbnail

Attributable risk proportion of uncontrolled low-density lipoprotein cholesterol in recurrent acute coronary syndromes

Speaker: Doctor E. Martinez Rey-Ranal (Elche, ES)

Thumbnail

Statin treatment in children with familial hypercholesterolemia in Scandinavia

Speaker: Doctor K. Svendsen (Oslo, NO)

Thumbnail

Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden

Speaker: Doctor E. Hagstrom (Uppsala, SE)

Thumbnail

Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES

Speaker: Professor G. Schwartz (Aurora, US)

Thumbnail

Access the full session

How good/bad are we in treating lipids

Speakers: Doctor Y. Fujihara, Doctor B. Gencer, Doctor E. Martinez Rey-Ranal, Doctor K. Svendsen, Doctor E. Hagstrom...
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk